Therapeutic Efficacy of Broadly Neutralizing SARS-CoV-2 Antibody

A 1.5 MB DOCX file details the characterization of a single-domain antibody, 1p2B5, targeting the N-terminal domain of the SARS-CoV-2 spike protein. Authored by Anastasia I. Korobkova and shared in March 2026, the document reports in vitro and in vivo data showing the antibody's broad neutralizing activity against diverse SARS-CoV-2 variants, including Omicron descendants. It includes therapeutic efficacy results from studies in Syrian hamsters and hACE2-transgenic mice.

Use Cases

• Analyze the reported nanomolar neutralizing potency of the 1p2B5-Fc antibody against diverse SARS-CoV-2 variants for therapeutic candidate assessment.
• Review the in vivo protection data from Syrian hamster and hACE2-transgenic mouse challenge models to evaluate cross-variant efficacy.
• Examine the characterization of the N-terminal domain (NTD) epitope as a target for broadly neutralizing antibodies against SARS-CoV-2 evolution.

Strengths

• Document is recently updated (March 2026), providing contemporary research on SARS-CoV-2 variant resistance.
• Data includes specific, quantitative results such as a 1 mg/kg therapeutic dose and nanomolar neutralizing activity.
• Research covers multiple experimental models, including in vitro assays and two distinct animal challenge models (hamsters and transgenic mice).

Limitations

• The dataset is a single 1.5 MB DOCX document, not a structured, machine-readable table, limiting computational analysis.
• No explicit columnar data, sample data, or row count is provided, requiring manual extraction of numerical results from text.
• The scope is focused on a single antibody candidate (1p2B5), limiting broader comparative analyses across therapeutic antibodies.

Provenance

Source

figshare, authored by Anastasia I. Korobkova.

Collection Method

Experimental research documenting antibody characterization, in vitro neutralization assays, and in vivo animal challenge studies.

Freshness

Last updated March 2026.